Sign in
TerminatedPhase 2

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Bethesda, United StatesSee the location
Trial code
Status
Terminated
Phase
Phase 2
People taking part
12 people enrolled
Started
9 Jun 2020
Ended
5 Sept 2024
Type of study
Interventional, 3 groups
Treatments tested
  • Paclitaxel
  • Capecitabine
  • BardPort Titanium Implanted Port with Peritoneal Catheter
Record updated
5 May 2026
Why it stopped
Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment in another study.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who cannot take part

  • Patients who are receiving any other investigational agents
  • Previous cytoreductive surgery or intraperitoneal chemotherapy
  • Previous treatment with paclitaxel or nab-paclitaxel resulting in progression of disease
  • Pregnant women are excluded because paclitaxel and capecitabine can cause fetal harm when administered to pregnant women. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel and capecitabine, breastfeeding should be discontinued if the mother is treated with paclitaxel and capecitabine
  • Disseminated extra-peritoneal or solid organ metastases:; Excludes greater omentum and ovarian metastases; Radiographic signs or clinical symptoms consistent with malignant bowel obstruction
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Paclitaxel or Capecitabine or other agents used in study
  • Past medical history of dihydropyrimidine dehydrogenase deficiency
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Existing peripheral neuropathy, Grade 3 or greater

Other criteria

  • -INCLUSION CRITERIA:
  • Patients must have histologically or cytologically confirmed gastric adenocarcinoma, including Siewert III gastroesophageal junction adenocarcinoma, confirmed by the National Cancer Institute (NCI) Laboratory of Pathology, and have provided a block or unstained slides of primary or; metastatic tumor tissue or newly obtained fresh biopsy of a tumor lesion in case archival tissue sample is not available
  • Patients may be treatment naive or have received systemic chemotherapy prior to enrollment:; Trastuzumab allowed as prior treatment for human epidermal growth factor receptor 2 (HER2)/neu over-expressing cancers as clinically indicated; Last dose of chemotherapy at least 2 weeks prior to enrollment with recovery to Grade 1 from chemotherapy-related toxicities
  • Radiographic evidence of peritoneal carcinomatosis and/or sub-radiographic evidence of peritoneal carcinomatosis found at staging laparoscopy
  • Age >=18 years. Children under the age of 18 will not participate in this study as gastric cancer is rare in this population
  • Eastern Cooperative Oncology Group (ECOG) performance status <=1
  • Patients must have normal organ and marrow function as defined below:; hemoglobin >=8.0 g/dL; absolute neutrophil count >=1,000/mcL; platelets >=100,000/mcL; total bilirubin <=1.5 X institutional upper limit of normal; Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) <=2.5 X institutional upper limit of normal; creatinine <1.5 mg/dl; OR; creatinine clearance >=60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal
  • Physiologically able to undergo laparoscopy and systemic chemotherapy
  • Ability of subject to understand and the willingness to sign a written informed consent document
  • Previous exploratory laparotomy or laparoscopy with tissue biopsy or peritoneal lavage is permitted
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Patients must be co-enrolled in protocol 13C0176 (NCT01915225) and 17C0044 (NCT03027427) for sample collection
  • Human immunodeficiency virus (HIV)-positive patients may be considered for this study only after consultation with a National Institute of Allergy and Infectious Diseases (NIAID) physician

1 location in United States

  • National Institutes of Health Clinical CenterBethesda, United States

What happens in this trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live longer and delay the time it takes for the cancer to grow.

Objective:

To find a better way to treat advanced stomach cancer.

Eligibility:

People ages 18 and older with stomach cancer that has spread throughout their belly.

Design:

Participants will be screened with:

Medical history

Physical exam

Blood, urine, and heart tests

Scans

Cancer sample: If they do not have one, they will have a biopsy.

Tests of performance of normal activities

Dietary assessment

Participants will have a laparoscopy. Small cuts are made into their abdomen. A thin camera with a light is inserted. Small instruments are used to take biopsies. This will be repeated during the study to monitor the cancer. During the first laparoscopy, a port with a catheter attached will be put into the abdomen.

Participants may also have an endoscopy: A thin tube with a camera is inserted through the mouth and into the stomach. The tube collects samples to monitor the cancer.

Participants will get paclitaxel every 3 weeks through the abdominal port and through a small plastic tube in an arm vein. They will also take capecitabine by mouth twice daily for the first 15 days of a 21-day cycle.

After participants finish 3 cycles, they will have scans to see how they are doing. They may get another course of therapy.

Participants will have visits every 3 weeks during treatment. Then they will have follow-up visits for 5 years. Then they will keep in touch with researchers for the rest of their life.

The 3 groups in the trial

  • Paclitaxel Intraperitoneal 20mg & Intravenous 80mg Every 3Weeks & Capecitabine 825mg/m^2 Twice DailyTreatment being tested

    Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine

    Treatment: Paclitaxel, Capecitabine, and BardPort Titanium Implanted Port with Peritoneal Catheter

  • Paclitaxel Intraperitoneal 60mg & Intravenous 80mg Every 3Weeks &Capecitabine 825mg/m^2 Twice DailyTreatment being tested

    Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine

    Treatment: Paclitaxel, Capecitabine, and BardPort Titanium Implanted Port with Peritoneal Catheter

  • Paclitaxel Intraperitoneal & Intravenous Every 3 Weeks & Capecitabine Twice DailyTreatment being tested

    Intraperitoneal (IP) and intravenous (IV) paclitaxel administration with concomitant oral capecitabine

    Treatment: Paclitaxel, Capecitabine, and BardPort Titanium Implanted Port with Peritoneal Catheter

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Record updated
5 May 2026